Skip to main content
Erschienen in:

11.06.2024 | Typ-2-Diabetes | Fortbildung

Non-HDL-Cholesterin als Ziel der Lipidtherapie bei Diabetes

Risikofaktor für kardiovaskuläre Erkrankungen

verfasst von: Dr. med. Julia Brandts

Erschienen in: CardioVasc | Ausgabe 3/2024

Einloggen, um Zugang zu erhalten

Auszug

Triglyzeridreiche Lipoproteine sind bei Diabetikern oft erhöht. Das darin enthaltene Apolipoprotein B bestimmt das kardiovaskuläre Risiko, ist aber teuer zu messen. Hier ist Non-HDL-C eine einfache Alternative und ein guter Risikoindikator. Wie es als Therapieziel genutzt werden kann, ist hier zusammengefasst. …
Literatur
1.
Zurück zum Zitat Sabatine MS, Leiter LA, Wiviott SD et al. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. The lancet Diabetes & endocrinology. 2017;5(12):941-50 Sabatine MS, Leiter LA, Wiviott SD et al. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. The lancet Diabetes & endocrinology. 2017;5(12):941-50
2.
Zurück zum Zitat Ference BA, Kastelein JJ, Ray KK et al. Association of triglyceride-lowering LPL variants and LDL-C-lowering LDLR variants with risk of coronary heart disease. JAMA. 2019;321(4):364-73 Ference BA, Kastelein JJ, Ray KK et al. Association of triglyceride-lowering LPL variants and LDL-C-lowering LDLR variants with risk of coronary heart disease. JAMA. 2019;321(4):364-73
3.
Zurück zum Zitat Pradhan AD, Glynn RJ, Fruchart J-C et al. Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk. New England Journal of Medicine. 2022;387(21):1923-34 Pradhan AD, Glynn RJ, Fruchart J-C et al. Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk. New England Journal of Medicine. 2022;387(21):1923-34
4.
Zurück zum Zitat AIM-HIGH Investigators; Boden WE, Probstfield JL et al. Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy. New England Journal of Medicine. 2011;365(24):2255-67 AIM-HIGH Investigators; Boden WE, Probstfield JL et al. Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy. New England Journal of Medicine. 2011;365(24):2255-67
5.
Zurück zum Zitat Boekholdt SM, Arsenault BJ, Mora S et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA. 2012;307(12):1302-9 Boekholdt SM, Arsenault BJ, Mora S et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA. 2012;307(12):1302-9
6.
Zurück zum Zitat Liao P, Zeng R, Zhao X et al. Prognostic value of non-high-density lipoprotein cholesterol for mortality in patients with coronary heart disease: a systematic review and meta-analysis. International journal of cardiology. 2017;227:950-5 Liao P, Zeng R, Zhao X et al. Prognostic value of non-high-density lipoprotein cholesterol for mortality in patients with coronary heart disease: a systematic review and meta-analysis. International journal of cardiology. 2017;227:950-5
7.
Zurück zum Zitat Marx N, Federici M, Schütt K et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes: Developed by the task force on the management of cardiovascular disease in patients with diabetes of the European Society of Cardiology (ESC). European heart journal. 2023;44(39):4043-140 Marx N, Federici M, Schütt K et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes: Developed by the task force on the management of cardiovascular disease in patients with diabetes of the European Society of Cardiology (ESC). European heart journal. 2023;44(39):4043-140
8.
Zurück zum Zitat Vallejo-Vaz AJ, Fayyad R, Boekholdt SM et al. Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial. Circulation. 2018;138(8):770-81 Vallejo-Vaz AJ, Fayyad R, Boekholdt SM et al. Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial. Circulation. 2018;138(8):770-81
9.
Zurück zum Zitat Cannon CP, Blazing MA, Giugliano RP et al. Ezetimibe added to statin therapy after acute coronary syndromes. New England Journal of Medicine. 2015;372(25):2387-97 Cannon CP, Blazing MA, Giugliano RP et al. Ezetimibe added to statin therapy after acute coronary syndromes. New England Journal of Medicine. 2015;372(25):2387-97
10.
Zurück zum Zitat Nissen SE, Lincoff AM, Brennan D et al. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. New England Journal of Medicine. 2023;388(15):1353-64 Nissen SE, Lincoff AM, Brennan D et al. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. New England Journal of Medicine. 2023;388(15):1353-64
11.
Zurück zum Zitat Ray KK, Nicholls SJ, Li N et al. Efficacy and safety of bempedoic acid among patients with and without diabetes: prespecified analysis of the CLEAR Outcomes randomised trial. The Lancet Diabetes & Endocrinology. 2024;12(1):19-28 Ray KK, Nicholls SJ, Li N et al. Efficacy and safety of bempedoic acid among patients with and without diabetes: prespecified analysis of the CLEAR Outcomes randomised trial. The Lancet Diabetes & Endocrinology. 2024;12(1):19-28
12.
Zurück zum Zitat Ray KK, Leiter LA, Müller-Wieland D et al. Alirocumab vs usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: the ODYSSEY DM-DYSLIPIDEMIA randomized trial. Diabetes, Obesity and Metabolism. 2018;20(6):1479-89 Ray KK, Leiter LA, Müller-Wieland D et al. Alirocumab vs usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: the ODYSSEY DM-DYSLIPIDEMIA randomized trial. Diabetes, Obesity and Metabolism. 2018;20(6):1479-89
13.
Zurück zum Zitat Loss-of-Function Mutations in APOC3, Triglycerides, and Coronary Disease. New England Journal of Medicine. 2014;371(1):22-31 Loss-of-Function Mutations in APOC3, Triglycerides, and Coronary Disease. New England Journal of Medicine. 2014;371(1):22-31
14.
Zurück zum Zitat Witztum JL, Gaudet D, Freedman SD et al. Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome. New England Journal of Medicine. 2019;381(6):531-42 Witztum JL, Gaudet D, Freedman SD et al. Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome. New England Journal of Medicine. 2019;381(6):531-42
15.
Zurück zum Zitat Dewey FE, Gusarova V, Dunbar RL et al. Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease. N Engl J Med. 2017;377(3):211-221 Dewey FE, Gusarova V, Dunbar RL et al. Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease. N Engl J Med. 2017;377(3):211-221
16.
Zurück zum Zitat Graham MJ, Lee RG, Brandt TA et al. Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides. N Engl J Med. 2017 Jul 20;377(3):222-232 Graham MJ, Lee RG, Brandt TA et al. Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides. N Engl J Med. 2017 Jul 20;377(3):222-232
17.
Zurück zum Zitat Bergmark BA, Marston NA, Bramson CR et al. Effect of Vupanorsen on Non-High-Density Lipoprotein Cholesterol Levels in Statin-Treated Patients With Elevated Cholesterol: TRANSLATE-TIMI 70. Circulation. 2022;145(18):1377-86 Bergmark BA, Marston NA, Bramson CR et al. Effect of Vupanorsen on Non-High-Density Lipoprotein Cholesterol Levels in Statin-Treated Patients With Elevated Cholesterol: TRANSLATE-TIMI 70. Circulation. 2022;145(18):1377-86
Metadaten
Titel
Non-HDL-Cholesterin als Ziel der Lipidtherapie bei Diabetes
Risikofaktor für kardiovaskuläre Erkrankungen
verfasst von
Dr. med. Julia Brandts
Publikationsdatum
11.06.2024
Verlag
Springer Medizin
Erschienen in
CardioVasc / Ausgabe 3/2024
Print ISSN: 1617-4933
Elektronische ISSN: 1618-3851
DOI
https://doi.org/10.1007/s15027-024-3575-2

Weitere Artikel der Ausgabe 3/2024

CardioVasc 3/2024 Zur Ausgabe

Praxisempfehlungen der Deutschen Diabetes Gesellschaft

Kurz, prägnant und aktuell: Die Praxisempfehlungen der Deutschen Diabetes Gesellschaft.